Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
journal contribution
posted on 2019-08-23, 15:59 authored by TA Eyre, HS Walter, S Iyengar, G Follows, M Cross, CP Fox, A Hodson, J Coats, S Narat, N Morley, MJS Dyer, GP CollinsMantle cell lymphoma (MCL), an aggressive B-cell malignancy accounting for 6% of non-Hodgkin lymphomas, remains incurable with standard therapy. Despite the approval of bortezomib,1 temsirolimus,2 lenalidomide,3 ibrutinib4 and acalabrutinib,5 patients with relapsed, refractory MCL have a survival of 2 years.
History
Related Materials
- 1.
Citation
Haematologica, 2018 vol. 104 no. 2 e68-e71Author affiliation
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Cancer Research CentreVersion
- VoR (Version of Record)
Published in
HaematologicaPublisher
Ferrata Storti Foundationeissn
1592-8721Acceptance date
2018-08-31Copyright date
2018Available date
2019-08-23Publisher DOI
Language
enAdministrator link
Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC